Director Frank Morich of Perspective Therapeutics, Inc. (NYSE:CATX) filed a statement of changes in beneficial ownership on November 17, 2026, disclosing a purchase of common stock on November 16, 2026.

Key Highlights

  • Director purchase: Frank Morich acquired 15,000 shares of Perspective Therapeutics common stock on November 16, 2026.
  • Price per share: The transaction was reported at $0.9364 per share, converted from EUR 0.85 per share using an exchange rate of USD 1.1016 per EUR, according to the filing.
  • Post-transaction ownership: Following the purchase, Morich directly holds 30,000 shares of common stock, the filing discloses.
  • Transaction code: The filing records a transaction code of "P," indicating an open-market purchase.
  • Euro-denominated trade: The filing notes the purchase was made in euros, with the reported U.S. dollar price reflecting a currency conversion.

Morich's November 2026 Open-Market Purchase of CATX Common Stock

According to the filing, Frank Morich, a director of Perspective Therapeutics, Inc. (NYSE:CATX), acquired 15,000 shares of the company's common stock on November 16, 2026, through an open-market purchase. The transaction was denominated in euros at EUR 0.85 per share and converted to a reported U.S. dollar price of $0.9364 per share using an exchange rate of USD 1.1016 per EUR, as explained in the filing's footnote.

Perspective Therapeutics is a clinical-stage radiopharmaceutical company. The filing identifies Morich solely as a director and does not attribute any officer title to him. The form was signed by Chris Nenno as attorney-in-fact for Morich and submitted on November 17, 2026. The filing reflects direct ownership of the shares, with no indirect beneficial ownership reported for this transaction.

Prior to the reported transaction, Morich held 15,000 shares directly, and the acquisition of an additional 15,000 shares brought his total direct beneficial ownership to 30,000 shares of common stock, as stated in Table I of the filing. No derivative securities transactions were reported in Table II.

What Was Disclosed

The filing disclosed a single open-market purchase by Director Frank Morich of 15,000 shares of Perspective Therapeutics common stock at $0.9364 per share on November 16, 2026, bringing his total direct holdings to 30,000 shares.